Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival

Success of immune checkpoint inhibitors in advanced non-small-cell lung cancer (NSCLC) has invigorated their use in the neoadjuvant setting for early-stage disease. However, the cellular and molecular mechanisms of the early immune responses to therapy remain poorly understood. Through an integrated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Markowitz, Geoffrey J., Havel, Lauren S., Crowley, Michael J.P., Ban, Yi, Lee, Sharrell B., Thalappillil, Jennifer S., Narula, Navneet, Bhinder, Bhavneet, Elemento, Olivier, Wong, Stephen T.C., Gao, Dingcheng, Altorki, Nasser K., Mittal, Vivek
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6101707/
https://ncbi.nlm.nih.gov/pubmed/29997286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.96836
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados